Use of an anti-CD200 antibody for prolonging the survival of allografts: a patent evaluation of WO2012106634A1.
BACKGROUND
Allograft rejection continues to be the biggest hurdle in successful organ transplantation. This application (WO2012106634A1) claims the use of blocking CD200 antibody to achieve long-term survival of allografts. CD200 is the ligand for the inhibitory CD200 receptor (CD200R).


METHODS
In mouse allograft transplantation models, a blocking CD200 antibody was used to improve renal and cardiac graft survival. Similarly, in humans a blocking CD200 antibody would be administered to the organ recipient in combination with currently used immunosuppressive drugs or even as a monotherapy.


RESULTS
In the presented animal experiments, anti-CD200 antibody application to the allograft recipient decreases SHIP expression in splenocytes. This is accompanied by a significant increase in renal or cardiac graft survival. Furthermore, anti-CD200 antibody has an immunosuppressive effect manifested by an increased production of T regulatory and myeloid-derived suppressor cells (MDSC) and a decrease in B cells and activated T cells.


CONCLUSIONS
In vivo administration of anti-CD200 antibody has a remarkable positive effect on allograft survival. However, since this finding contradicts all previous effects of in vivo CD200 manipulation described in transplantation settings, future development of this invention is highly uncertain.
Department of Immunology, Medical University of Warsaw, Center of Biostructure Research, Warsaw, Poland.
Tomasz P
TP
Rygiel
Bart
B
Luijk
Linde
L
Meyaard
D000818:Animals; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D006085:Graft Survival / Q000187:drug effects*; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology; D051379:Mice; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects
D019138:Antibodies, Blocking; D015703:Antigens, CD; D007166:Immunosuppressive Agents; C042739:antigens, CD200